Literature DB >> 24445728

Genetic polymorphisms of proangiogenic factors seem to favor hepatocellular carcinoma development in alcoholic cirrhosis.

Mariana V Machado1, André Janeiro, Gabriel Miltenberger-Miltenyi, Helena Cortez-Pinto.   

Abstract

OBJECTIVE: Angiogenesis has been associated with hepatic cirrhosis and hepatocellular carcinoma (HCC). Alcohol promotes liver hypoxia, a trigger of angiogenesis. We aimed to evaluate whether the frequency of three polymorphisms in hypoxia-induced factor-1α (HIF-1α), vascular endothelial growth factor A (VEGFA), and KDR (encoding vascular endothelial growth factor receptor 2) genes was higher in alcoholics presenting liver disease (ALD) and ALD patients who developed HCC.
MATERIALS AND METHODS: Functional HIF-1α 1744C/T, VEGFA 2578C/A, and KDR 1416A/T single-nucleotide polymorphisms were studied in 125 ALD patients and 88 heavy drinkers without liver disease (NLD). ALD patients were followed up to 9 years or until they died; 26 patients developed HCC.
RESULTS: ALD patients were older than NLD (56±11 vs. 50±13, P<0.001), but drank less (215±164 vs. 331±293 g/day, P<0.001). No differences were found between HIF-1α, VEGFA, or KDR allelic frequencies or genotypes, isolated or simultaneously, between ALD and NLD. In ALD patients, those who developed HCC had a higher KDR 1416T allele frequency (36 vs. 15%, P=0.004; odds ratio 2.72; 95% confidence interval 1.35-5.46). There was also a progressive increase in genotypes with one or two T alleles in patients who developed HCC: AA 50 vs. 73%, AT 35 vs. 23%, and TT 15 vs. 4% (P=0.009). The simultaneous presence of KDR 1416T and VEGFA 2578A was associated with an increased risk of HCC (odds ratio 3.088; 95% confidence interval 1.20-7.96).
CONCLUSION: Genetic polymorphisms in proangiogenic factors did not associate with the risk of ALD in heavy drinkers. However, KDR and VEFGA polymorphisms may confer an increased risk of HCC in patients with ALD.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24445728     DOI: 10.1097/MEG.0000000000000044

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  7 in total

1.  Epidermal growth factor receptor pathway polymorphisms and the prognosis of hepatocellular carcinoma.

Authors:  Wenjia Wang; Xiao-Pin Ma; Zhuqing Shi; Pengyin Zhang; Dong-Lin Ding; Hui-Xing Huang; Hexi Ge Saiyin; Tao-Yang Chen; Pei-Xin Lu; Neng-Jin Wang; Hongjie Yu; Jielin Sun; S Lilly Zheng; Long Yu; Jianfeng Xu; De-Ke Jiang
Journal:  Am J Cancer Res       Date:  2014-12-15       Impact factor: 6.166

2.  Screening potential prognostic biomarkers for portal vein emboli in patients with hepatocellular carcinoma.

Authors:  Weijie Zhou; Da Lang Fang; Yongfei He
Journal:  J Gastrointest Oncol       Date:  2021-08

3.  Impact of VEGFA promoter polymorphisms on esophageal cancer risk in North-West Indians: a case-control study.

Authors:  Kamlesh Guleria; Simranjot Kaur; Deepanshi Mahajan; Vasudha Sambyal; Meena Sudan; Manjit Singh Uppal
Journal:  Genes Genomics       Date:  2022-06-29       Impact factor: 2.164

4.  Development of an in vitro model to test antifibrotic drugs on primary human liver myofibroblasts.

Authors:  Lynda Aoudjehane; Pierre-Yves Boelle; Grégoire Bisch; Rolland Delelo; François Paye; Olivier Scatton; Chantal Housset; Jérôme Becquart; Yvon Calmus; Filomena Conti
Journal:  Lab Invest       Date:  2016-03-07       Impact factor: 5.662

Review 5.  Role of HIF-1α in Alcohol-Mediated Multiple Organ Dysfunction.

Authors:  Niya L Morris; Samantha M Yeligar
Journal:  Biomolecules       Date:  2018-12-10

6.  Associations between twelve common gene polymorphisms and susceptibility to hepatocellular carcinoma: evidence from a meta-analysis.

Authors:  Yi Quan; Jun Yang; Tao Qin; Yufang Hu
Journal:  World J Surg Oncol       Date:  2019-12-12       Impact factor: 2.754

7.  Nonalcoholic Cirrhosis Increased Risk of Digestive Tract Malignancies: A Population-Based Cohort Study.

Authors:  Li-Min Sun; Ming-Chia Lin; Cheng-Li Lin; Ji-An Liang; Long-Bin Jeng; Chia-Hung Kao; Chiao-Yi Lu
Journal:  Medicine (Baltimore)       Date:  2015-12       Impact factor: 1.817

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.